B
ECYT

Bailard’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Bailard’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-56,000
Closed -$351K – 262
2015
Q1 		$351K Hold
56,000
– – 0.05% 174
2014
Q4 		$352K Sell
56,000
-55,000
-50% -$335K 0.05% 174
2014
Q3 		$675K Hold
111,000
– – 0.1% 109
2014
Q2 		$731K Hold
111,000
– – 0.11% 106
2014
Q1 		$2.64M Buy
111,000
+56,000
+102% +$812K 0.42% 33
2013
Q4 		$587K Hold
55,000
– – 0.09% 118
2013
Q3 		$733K Sell
55,000
-54,100
-50% -$855K 0.14% 121
2013
Q2 		$1.43M Buy
+109,100
New +$1.47M 0.26% 82

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bailard's ECYT Position: Q2 2015 in Review

Bailard sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2015, closing a stake of 56,000 shares — an estimated $351K sold.

Bailard first reported a position in ECYT in Q2 2013 and held it in 8 quarters. The position peaked at $2.64M in Q1 2014. 98 funds tracked by Wall St. Rank hold ECYT as of Q2 2015.

  • Bailard reported no remaining Endocyte, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • Bailard sold 56,000 Endocyte, Inc. Common Stock shares in Q2 2015, an estimated $351K.
  • Bailard first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 8 quarters.
  • Bailard's Endocyte, Inc. Common Stock position peaked at $2.64M in Q1 2014.
  • 98 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2015.

Based on Bailard's 13F filing for Q2 2015, filed 6 Aug 2015.